company background image
5002

Morepen LaboratoriesBSE:500288 Stock Report

Market Cap

₹24.6b

7D

-2.5%

1Y

98.2%

Updated

15 Oct, 2021

Data

Company Financials
500288 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance6/6
Financial Health4/6
Dividends0/6

500288 Overview

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India.

Price History & Performance

Summary of all time highs, changes and price drops for Morepen Laboratories
Historical stock prices
Current Share Price₹54.70
52 Week High₹24.50
52 Week Low₹75.00
Beta1.2
1 Month Change-7.68%
3 Month Change-18.11%
1 Year Change98.19%
3 Year Change132.77%
5 Year Change123.72%
Change since IPO-50.72%

Recent News & Updates

Shareholder Returns

500288IN PharmaceuticalsIN Market
7D-2.5%0.6%2.3%
1Y98.2%23.5%68.3%

Return vs Industry: 500288 exceeded the Indian Pharmaceuticals industry which returned 24.7% over the past year.

Return vs Market: 500288 exceeded the Indian Market which returned 69.5% over the past year.

Price Volatility

Is 500288's price volatile compared to industry and market?
500288 volatility
500288 Beta1.2
Industry Beta0.60
Market Beta1

Stable Share Price: 500288 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 500288's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19841,510Sushil Surihttps://www.morepen.com

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac.

Morepen Laboratories Fundamentals Summary

How do Morepen Laboratories's earnings and revenue compare to its market cap?
500288 fundamental statistics
Market Cap₹24.61b
Earnings (TTM)₹1.08b
Revenue (TTM)₹13.29b

22.7x

P/E Ratio

1.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
500288 income statement (TTM)
Revenue₹13.29b
Cost of Revenue₹8.91b
Gross Profit₹4.39b
Expenses₹3.30b
Earnings₹1.08b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)2.41
Gross Margin32.99%
Net Profit Margin8.14%
Debt/Equity Ratio43.7%

How did 500288 perform over the long term?

See historical performance and comparison

Valuation

Is Morepen Laboratories undervalued compared to its fair value and its price relative to the market?

22.74x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 500288 (₹54.7) is trading above our estimate of fair value (₹12.41)

Significantly Below Fair Value: 500288 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 500288 is good value based on its PE Ratio (22.7x) compared to the Indian Pharmaceuticals industry average (26x).

PE vs Market: 500288 is poor value based on its PE Ratio (22.7x) compared to the Indian market (22.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 500288's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 500288 is overvalued based on its PB Ratio (5.8x) compared to the IN Pharmaceuticals industry average (3.2x).


Future Growth

How is Morepen Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Morepen Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Morepen Laboratories performed over the past 5 years?

40.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 500288 has high quality earnings.

Growing Profit Margin: 500288's current net profit margins (8.1%) are higher than last year (4.9%).


Past Earnings Growth Analysis

Earnings Trend: 500288's earnings have grown significantly by 40.5% per year over the past 5 years.

Accelerating Growth: 500288's earnings growth over the past year (138.9%) exceeds its 5-year average (40.5% per year).

Earnings vs Industry: 500288 earnings growth over the past year (138.9%) exceeded the Pharmaceuticals industry 35.8%.


Return on Equity

High ROE: 500288's Return on Equity (25.5%) is considered high.


Financial Health

How is Morepen Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: 500288's short term assets (₹5.3B) exceed its short term liabilities (₹4.0B).

Long Term Liabilities: 500288's short term assets (₹5.3B) exceed its long term liabilities (₹300.6M).


Debt to Equity History and Analysis

Debt Level: 500288's debt to equity ratio (43.7%) is considered high.

Reducing Debt: 500288's debt to equity ratio has increased from 34% to 43.7% over the past 5 years.

Debt Coverage: 500288's debt is well covered by operating cash flow (27.4%).

Interest Coverage: 500288's interest payments on its debt are well covered by EBIT (69.6x coverage).


Balance Sheet


Dividend

What is Morepen Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 500288's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 500288's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 500288's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 500288's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 500288's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.0yrs

Average management tenure


CEO

Sushil Suri (57 yo)

21yrs

Tenure

₹53,852,000

Compensation

Mr. Sushil Suri, B.Sc., FCA has been Managing Director of Morepen Laboratories Limited since October 2000. He has been Chairman of Morepen Laboratories Limited since October 2000 and has been its Director...


CEO Compensation Analysis

Compensation vs Market: Sushil's total compensation ($USD716.55K) is above average for companies of similar size in the Indian market ($USD287.82K).

Compensation vs Earnings: Sushil's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: 500288's management team is seasoned and experienced (7 years average tenure).


Board Members

Experienced Board: 500288's board of directors are seasoned and experienced ( 16.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Morepen Laboratories Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Morepen Laboratories Limited
  • Ticker: 500288
  • Exchange: BSE
  • Founded: 1984
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹24.605b
  • Shares outstanding: 449.83m
  • Website: https://www.morepen.com

Number of Employees


Location

  • Morepen Laboratories Limited
  • 409, Antriksh Bhawan
  • 4th Floor
  • New Delhi
  • Delhi
  • 110001
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/15 12:02
End of Day Share Price2021/10/14 00:00
Earnings2021/06/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.